PT3577110T - Compostos substituídos de 8-oxetan-3-il-3,8-diazabiciclo[3.2.1]octan-3-il como inibidores de vih - Google Patents

Compostos substituídos de 8-oxetan-3-il-3,8-diazabiciclo[3.2.1]octan-3-il como inibidores de vih

Info

Publication number
PT3577110T
PT3577110T PT187060728T PT18706072T PT3577110T PT 3577110 T PT3577110 T PT 3577110T PT 187060728 T PT187060728 T PT 187060728T PT 18706072 T PT18706072 T PT 18706072T PT 3577110 T PT3577110 T PT 3577110T
Authority
PT
Portugal
Prior art keywords
atazanavir
atv
analogues
treating hiv
hiv infections
Prior art date
Application number
PT187060728T
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61244746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3577110(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PT3577110T publication Critical patent/PT3577110T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)
PT187060728T 2017-02-06 2018-02-05 Compostos substituídos de 8-oxetan-3-il-3,8-diazabiciclo[3.2.1]octan-3-il como inibidores de vih PT3577110T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762455348P 2017-02-06 2017-02-06

Publications (1)

Publication Number Publication Date
PT3577110T true PT3577110T (pt) 2021-06-17

Family

ID=61244746

Family Applications (2)

Application Number Title Priority Date Filing Date
PT187060728T PT3577110T (pt) 2017-02-06 2018-02-05 Compostos substituídos de 8-oxetan-3-il-3,8-diazabiciclo[3.2.1]octan-3-il como inibidores de vih
PT211658356T PT3909949T (pt) 2017-02-06 2018-02-05 Análogos de atazanavir (atv) para tratar infeções por vih

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT211658356T PT3909949T (pt) 2017-02-06 2018-02-05 Análogos de atazanavir (atv) para tratar infeções por vih

Country Status (35)

Country Link
US (6) US10294234B2 (pt)
EP (3) EP3577110B1 (pt)
JP (4) JP6814304B2 (pt)
KR (5) KR102949652B1 (pt)
CN (3) CN115991708A (pt)
AR (1) AR110922A1 (pt)
AU (3) AU2018215546B2 (pt)
CA (1) CA3051588C (pt)
CL (1) CL2019002204A1 (pt)
CO (1) CO2019008531A2 (pt)
CR (1) CR20190354A (pt)
CY (1) CY1124276T1 (pt)
DK (2) DK3909949T3 (pt)
DO (1) DOP2019000201A (pt)
EA (1) EA201991684A1 (pt)
ES (2) ES3057738T3 (pt)
FI (1) FI3909949T3 (pt)
HR (2) HRP20251629T1 (pt)
HU (1) HUE054690T2 (pt)
IL (1) IL268282B2 (pt)
JO (1) JOP20180009A1 (pt)
LT (2) LT3577110T (pt)
MX (2) MX2019009212A (pt)
MY (2) MY200608A (pt)
PE (1) PE20191260A1 (pt)
PH (1) PH12019501786A1 (pt)
PL (2) PL3909949T3 (pt)
PT (2) PT3577110T (pt)
SA (1) SA519402405B1 (pt)
SG (1) SG11201907058TA (pt)
SI (2) SI3909949T1 (pt)
TW (4) TWI701243B (pt)
UA (1) UA123298C2 (pt)
UY (1) UY37592A (pt)
WO (1) WO2018145021A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
UY37592A (es) * 2017-02-06 2018-08-31 Gilead Sciences Inc Compuestos inhibidores del vih
TW202024061A (zh) * 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
TWI829205B (zh) * 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
CA3157275C (en) * 2019-11-26 2026-02-10 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
EP4153181B1 (en) 2020-05-21 2026-07-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
CN116390924B (zh) * 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
AU2022403012B2 (en) 2021-12-03 2026-02-12 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
AU2022399845B2 (en) 2021-12-03 2026-03-26 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
FI4440702T3 (fi) 2021-12-03 2025-08-08 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN119768183A (zh) 2022-08-26 2025-04-04 吉利德科学公司 用于广泛中和抗体的给药和安排方案
CN115215803B (zh) * 2022-09-19 2022-12-30 苏州美诺医药科技有限公司 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
EP4698174A1 (en) 2023-04-19 2026-02-25 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
EP4719602A1 (en) 2023-05-31 2026-04-08 Gilead Sciences, Inc. Anti-hiv compounds
WO2024249573A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
CN122295099A (zh) 2023-07-28 2026-06-26 吉利德科学公司 用于治疗和预防hiv的来那卡帕韦的每周方案
AU2023462614A1 (en) 2023-08-23 2026-03-19 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
IL327206A (en) 2023-10-11 2026-05-01 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their uses
AU2024360779A1 (en) 2023-10-11 2026-04-16 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
KR20260093341A (ko) 2023-10-11 2026-06-19 길리애드 사이언시즈, 인코포레이티드 가교 트리시클릭 카르바모일피리돈 화합물 및 이의 용도
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
TW202602461A (zh) 2024-04-03 2026-01-16 美商基利科學股份有限公司 抗ｈｉｖ化合物
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2026076265A1 (en) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2847064A1 (de) * 1978-10-28 1980-05-08 Boehringer Mannheim Gmbh Verwendung von 2-cyanaziridinen als therapeutica bei strahlenschaeden
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ATE143355T1 (de) 1991-07-03 1996-10-15 Ciba Geigy Ag Pharmakologisch wirksame hydrazinderivate und verfahren zu deren herstellung
US5753652A (en) 1991-07-03 1998-05-19 Novartis Corporation Antiretroviral hydrazine derivatives
AU2003200066B9 (en) 1992-03-11 2007-02-15 Narhex Limited Amine Derivatives of Oxo- and Hydroxy-substituted Hydrocarbons
BR9306058A (pt) 1992-03-11 1997-11-18 Narhex Ltd Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos
KR950701322A (ko) 1992-05-07 1995-03-23 조셉 에프. 디프리마 사람면역결핍바이러스 역전사효소의 억제제로서의 신규한 퀴나졸린(New quinazolines as inhibitors of HIV reversetranscriptase)
ES2093394T3 (es) 1992-12-23 1996-12-16 Ciba Geigy Ag Derivados de hidrazina antiretrovirales.
US5461067A (en) 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds
JPH11514996A (ja) 1995-11-21 1999-12-21 ノバルティス アクチエンゲゼルシャフト レトロウイルスアスパラギン酸プロテアーゼの置換同配体としてのアザヘキサン誘導体
TW409125B (en) 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997046514A1 (en) 1996-05-31 1997-12-11 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6451973B1 (en) 1996-07-17 2002-09-17 Novatis Ag Anilinopeptide derivatives
CH694251A5 (de) 1999-07-14 2004-10-15 Eprova Ag Herstellung von Tetrahydropterin und Derivaten.
ATE401298T1 (de) 1999-12-23 2008-08-15 Ampac Fine Chemicals Llc Verbessertes verfahren zur herstellung von 2s,3s- n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)- - nitrobenzenesulfonylamid hydrochlorid und anderen derivaten von 2-hydroxy-1,3-diamin
JP2004534771A (ja) 2001-05-22 2004-11-18 イーラン　ファーマスーティカルズ、インコーポレイテッド アザヒドロキシル化エチルアミン化合物
CA2449948A1 (en) 2001-06-08 2002-12-19 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease
JP2005506979A (ja) 2001-08-28 2005-03-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー オキソ置換及びヒドロキシ置換炭化水素のキナルドイル−アミン誘導体を使用するアルツハイマー病の治療方法
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
MXPA06006609A (es) 2003-12-11 2006-08-31 Abbott Lab Compuestos inhibidores de proteasa de vih.
US20050131042A1 (en) 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
RU2006134002A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
EP1773850B1 (en) 2004-07-06 2013-01-30 Abbott Laboratories Prodrugs of hiv protease inhibitors
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
KR20070110847A (ko) 2005-02-10 2007-11-20 메디비르 아베 Ｈｉｖ 프로테아제 억제제
CA2667445A1 (en) 2005-06-22 2007-01-04 University Of Massachusetts Hiv-1 protease inhibitors
GB0610242D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP5372751B2 (ja) * 2006-07-21 2013-12-18 ギリアード サイエンシーズ， インコーポレイテッド Ａｚａ−ペプチドプロテアーゼ阻害剤
PT2069303E (pt) * 2006-07-21 2016-06-08 Gilead Sciences Inc Inibidores de protease antiviral
US20100092149A1 (en) 2007-03-09 2010-04-15 Pioneer Corporation Av complex editing apparatus, av processor, and program
WO2008118849A2 (en) 2007-03-23 2008-10-02 University Of Massachusetts Hiv-1 protease inhibitors
MX2009013565A (es) 2007-06-12 2010-06-02 Concert Pharmaceuticals Inc Derivados de azapeptidos.
US8431608B2 (en) * 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
US8354429B2 (en) 2007-11-16 2013-01-15 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2009114151A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
EP2288593A1 (en) 2008-05-08 2011-03-02 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TWI466735B (zh) 2008-09-18 2015-01-01 傑士湯淺國際股份有限公司 紫外線照射裝置
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
US20120041019A1 (en) 2008-12-17 2012-02-16 Mutz Mitchell W Protease inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120108529A1 (en) 2009-05-15 2012-05-03 Webb Ii Robert R Protease inhibitors
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
CN102639492A (zh) 2009-07-29 2012-08-15 先灵公司 β-氨基-α-羟基酰胺的对映-和立体-有择合成
EP2292589A1 (en) 2009-09-02 2011-03-09 IMTM GmbH Novel multifunctional peptidase inhibitors, especially for medical use
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
CN102190638A (zh) * 2010-03-16 2011-09-21 中国科学院上海药物研究所 联芳基醇二胺类化合物、其药物组合物、制备方法及应用
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
CA2810005A1 (en) 2010-09-02 2012-03-08 Purdue Research Foundation Fused tricyclic ether carbamates and their use
WO2012092188A1 (en) 2010-12-27 2012-07-05 Ghosh Arun K Hydrogen bond forming p1 ligands and methods for treating hiv
US9024038B2 (en) 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
WO2012092168A1 (en) 2010-12-27 2012-07-05 Purdue Research Foundation Fused 6,5 bicyclic ring system p2 ligands, and methods for treating hiv
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
WO2012170792A1 (en) 2011-06-10 2012-12-13 Concert Pharmaceuticals, Inc. Atazanavir metabolite derivatives
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
JP6144698B2 (ja) 2011-12-20 2017-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｉｖ複製の阻害剤としての縮合三環式化合物
US9341365B2 (en) 2012-01-12 2016-05-17 Daniel L. Gan Eversible candle holder
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
HK1214817A1 (en) 2012-12-27 2016-08-05 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US20160002159A1 (en) * 2013-02-13 2016-01-07 Neal ZONDLO Perfluoro-tert-butyl hydroxyproline
US10035760B2 (en) 2013-10-24 2018-07-31 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2015097667A2 (en) 2013-12-23 2015-07-02 Cellworks Group, Inc., A composition, process of preparation of said composition, kit and a method of treating cancer
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015175704A1 (en) * 2014-05-14 2015-11-19 The Regents Of The University Of California Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
EP3142659B1 (en) 2014-05-16 2021-03-24 Purdue Research Foundation Hiv-1 protease inhibitors and uses thereof
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
AU2016250662A1 (en) 2015-04-23 2017-11-16 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MX2017014613A (es) 2015-05-15 2018-03-01 Gilead Sciences Inc Compuestos de bencimidazol e imadazopiridin-carboximidamida que tienen actividad como inhibidores de indolamina 2,3-dioxigenasa.
CN109996790B (zh) * 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
UY37592A (es) 2017-02-06 2018-08-31 Gilead Sciences Inc Compuestos inhibidores del vih
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
EP4719602A1 (en) 2023-05-31 2026-04-08 Gilead Sciences, Inc. Anti-hiv compounds

Also Published As

Publication number Publication date
UA123298C2 (uk) 2021-03-10
JP2021073287A (ja) 2021-05-13
PL3577110T3 (pl) 2021-10-25
PL3909949T3 (pl) 2026-02-23
CA3051588C (en) 2022-08-23
US20230027055A1 (en) 2023-01-26
MY207716A (en) 2025-03-14
MX2022012616A (es) 2022-11-07
FI3909949T3 (fi) 2025-12-31
IL268282B2 (en) 2023-02-01
US11078208B1 (en) 2021-08-03
SG11201907058TA (en) 2019-08-27
CO2019008531A2 (es) 2019-10-31
EP3577110B1 (en) 2021-04-21
NZ755929A (en) 2021-08-27
US10752636B2 (en) 2020-08-25
WO2018145021A1 (en) 2018-08-09
LT3909949T (lt) 2026-01-12
US20180258097A1 (en) 2018-09-13
CA3051588A1 (en) 2018-08-09
BR102018002152A2 (pt) 2018-10-30
TWI701243B (zh) 2020-08-11
JP7105853B2 (ja) 2022-07-25
BR102018002152A8 (pt) 2022-11-16
NZ776008A (en) 2025-10-31
US12084455B2 (en) 2024-09-10
LT3577110T (lt) 2021-07-12
MX2019009212A (es) 2019-09-27
TWI908223B (zh) 2025-12-11
CY1124276T1 (el) 2022-07-22
CN115991708A (zh) 2023-04-21
CN115093421A (zh) 2022-09-23
EP3577110A1 (en) 2019-12-11
EA201991684A1 (ru) 2020-02-11
JP2021046422A (ja) 2021-03-25
ES3057738T3 (en) 2026-03-04
EP4692076A1 (en) 2026-02-11
EP3909949A1 (en) 2021-11-17
HRP20210732T1 (hr) 2021-09-17
PH12019501786A1 (en) 2020-06-29
KR102430812B1 (ko) 2022-08-11
AU2018215546A1 (en) 2019-08-22
US20250042910A1 (en) 2025-02-06
TW202511265A (zh) 2025-03-16
TW202043219A (zh) 2020-12-01
UY37592A (es) 2018-08-31
US20260132139A1 (en) 2026-05-14
IL268282B (en) 2022-10-01
PT3909949T (pt) 2026-01-07
AU2020264300B2 (en) 2022-08-25
CN110536889B (zh) 2022-12-16
JOP20180009A1 (ar) 2019-01-30
AR110922A1 (es) 2019-05-15
JP2022172294A (ja) 2022-11-15
PE20191260A1 (es) 2019-09-18
DK3577110T3 (da) 2021-06-14
KR20260049348A (ko) 2026-04-13
KR20190115458A (ko) 2019-10-11
KR20230097222A (ko) 2023-06-30
KR102749565B1 (ko) 2025-01-03
JP7282112B2 (ja) 2023-05-26
IL268282A (en) 2019-09-26
EP3909949B1 (en) 2025-10-15
MY200608A (en) 2024-01-05
AU2018215546B2 (en) 2020-08-13
AU2022271510A1 (en) 2023-01-05
SI3909949T1 (sl) 2026-02-27
CN115093421B (zh) 2025-06-17
JP6814304B2 (ja) 2021-01-13
CR20190354A (es) 2019-09-19
TWI854464B (zh) 2024-09-01
US10294234B2 (en) 2019-05-21
KR102547909B1 (ko) 2023-06-28
TWI794629B (zh) 2023-03-01
HRP20251629T1 (hr) 2026-02-13
TW201840555A (zh) 2018-11-16
DK3909949T3 (da) 2026-01-12
TW202344506A (zh) 2023-11-16
CN110536889A (zh) 2019-12-03
DOP2019000201A (es) 2019-08-30
US12479853B2 (en) 2025-11-25
CL2019002204A1 (es) 2019-12-20
AU2020264300A1 (en) 2020-12-03
ES2877595T3 (es) 2021-11-17
US20190308983A1 (en) 2019-10-10
KR102949652B1 (ko) 2026-04-08
KR20250008988A (ko) 2025-01-16
SI3577110T1 (sl) 2021-08-31
JP2020506941A (ja) 2020-03-05
HUE054690T2 (hu) 2021-09-28
KR20220116340A (ko) 2022-08-22
SA519402405B1 (ar) 2024-03-03

Similar Documents

Publication Publication Date Title
LT3909949T (lt) Atazanaviro (atv) analogai, skirti živ infekcijų gydymui
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
GB201913722D0 (en) Adaptable processing components
SI3349758T1 (sl) Postopki za zdravljenje okužb z virusom arenaviridae
EP3252124A4 (en) Surface treatment agent
IL280327A (en) Thiazolide compounds for the treatment of viral infections
EP3543393A4 (en) CLOTHING TREATMENT DEVICE
EP3324987A4 (en) Bacteriophage for treating staphylococcus infections
PL3384915T3 (pl) Karymycyna do leczenia zakażeń prątkiem gruźlicy
GB2580285B (en) Packet processing graphs
IL271987A (en) Regimens for the treatment of HIV infections and AIDS
KR102330098B9 (ko) 기판 처리 장치
GB201908773D0 (en) Processing sibling calls
EP3396057A4 (en) Clothing processing device
IL258137B1 (en) HIV treatment measures
GB201712739D0 (en) Laser processing
EP3505924A4 (en) DEVICE FOR PROCESSING IMAGING DATA BY MASS SPECTROMETRY
PL3658174T3 (pl) Laktoferycyna i laktoferampina do leczenia infekcji
EP3296455A4 (en) Clothing treatment apparatus
ZA201901948B (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
PL3791095T3 (pl) Komponent procesowy
EP3296454A4 (en) Clothing treatment apparatus
ZA201900365B (en) Hiv infections
GB201719390D0 (en) Compounds useful against plasmodium infections
HK40006685A (en) Dihydropyranopyrimidines for the treatment of viral infections